Prostate Oncology Specialists

home : staff [ mark scholz cv :: richard lam cv :: duke bahn cv :: ]

CURRICULUM VITAE Richard Y. Lam

PERSONAL INFORMATION:
E-mail Address	richard@prostateoncology.com
Business Address	4676 Admiralty Way Suite # 101 Marina del Rey, CA 90292
Business Telephone	(310) 827-7707
Business Fax	(310) 574-4002

EDUCATION:
Undergraduate	University of California, Los Angeles Bachelor of Science, Biology. June 1990
Graduate	University of California, Los Angeles Doctor of Medicine. June 1994
POSTDOCTORAL TRAINING:
Internship	University of California, Los Angeles Center of Health Sciences Department of Internal Medicine. 1994-95
Residency	University of California, Los Angeles Center of Health Sciences Department of Internal Medicine. 1995-97
Fellowship	University of California, Los Angeles Harbor-UCLA Hospital Department of Internal Medicine Division of Medical Oncology and Hematology. 1998-2001
Work Experience	Kaiser Foundation Hospital of West Los Angeles Medical Emergency Room and Urgent Care Center Physician, 1997-98 Prostate Oncology Specialists Oncology Specialist, 2001-present

Certification and Licensure:
United States Medical Licensing Examination, Steps 1-31992-95 California Physicians and Surgeons License, 1996 Diplomat, American Board of Internal Medicine, 1997 Diplomat, American Board of Internal Medicine (Oncology), 2002

Honors and Awards:
Phi Beta Sigma National Honor Society, UCLA 1987 Outstanding Students of America Award, UCLA 1987 Golden Key National Honor Society, UCLA 1988 Graduated Magna Cum Laude, UCLA 1990 Phi Beta Kappa, UCLA 1990 Best Abstract, 1st Runner up. Western AUA, 2003.

Research Experience:
"Genetics of Retinitis Pigmentosa," Mentor: Bronwyn Bateman, MD, Jules Stein Eye Institute, UCLA, 1987-88 "Genetics of Sexual Reproduction in the Fruit Fly," Mentor: Frank Laski, Ph.D., Molecular Biology Institute, UCLA, 1990 "Effects of Androgen Ablation on Co-Morbid Disease in Prostate Cancer Patients," Mentor: Rowan Chlebowski, MD, Harbor-UCLA Medical Center, 1999

Publications:
Lam, R., Chlebowski, R. "Tamoxifen to Treat Premenopausal Women with Breast Cancer." Cancer Investigation, 18:681-684, 2000. Curti, M., Leung, M., Lam, R., Saeed, S., Gulati, P., Niihara, "Successful Treatment of a Patient with Pure Red Cell Aplasia with Prednisone, Cyclosporine, and Antithymocyte Globulin." Med Am, 2001. Scholz, M., Lam, R., Brosman, S., Guess, B., "Calcitriol restores docetaxel anticancer activity in men with androgen independent prostate cancer who previously progressed on docetaxel. Proc West AUA, 2003. Scholz, M., Lam, R., Brosman, S., Guess, B., "Extent of disease on bone scan, baseline alkaline phosphatase, and 80% decline in PSA are the best indicators predicting long-term survival in men with androgen independent prostate cancer treated with ketoconazole." Proc West AUA, 2003. Scholz, M., Trilling, T., Brosman, S., Guess, B., Johnson, H, Lam, R., "PSA nadir greater than 0.1 on combined hormone blockade predicts the early development of androgen independent prostate cancer in men with PSA relapse after local therapy." Proc West AUA, 2003. Lam, R., Scholz, M, Guess, B, Trilling, T, "Oral bisphosphonates for the prevention of androgen deprivation therapy-associated bone loss – preliminary findings." Proc ASCO, 2004. Scholz, M., Jennrich, R., Strum, S., Brosman, S., Johnson, H., Lam, R., "Long-term outcome for men with androgen independent prostate cancer treated with Ketoconazole and hydrocortisone." J of Urology, 173:1947-1952, 2005.

Lectures:
Tumor Board (Presenter and Discussant) Kaiser Permanente Bellflower. Weekly from October 1999 to April 2000 and November 2000 to February 2001. "Treatment Options for the Newly Diagnosed Prostate Cancer Patient." Physician Education Lecture, Daniel Freeman Medical Center. April 4, 2002. "Promising Experimental Drugs in Prostate Cancer." Prostate Cancer Patient Support Group, Marina Del Rey. November, 2001. "Ketoconazole for Androgen Independent Prostate Cancer." National Conference on Prostate Cancer, University of Southern California. October 4, 2002. "Management of Relapsed Prostate Cancer," Prostate Cancer Patient Support Group, Mercy Hospital of Bakersfield. April 1, 2003. "Medical Options for Relapsed Prostate Cancer." Prostate Cancer Patient Support Group, Holy Cross Medical Center. July 15, 2003. "Nizoral-Promising Results for a Treatment Often Overlooked." National Conference on Prostate Cancer, Burbank Hilton Convention Center. September 7, 2003. "Management of Toxicities Related to Androgen Deprivation Therapy." Southern California Radiological Society. Jan 23, 2004. "Approach to a Newly Diagnosed Prostate Cancer Patient." Wellness Community, Santa Monica, California. February 9, 2004. "Management of Toxicities Related to Androgen Deprivation Therapy." Prostate Cancer Support Group, Marina Del Rey. February 19, 2004. "Approach to a Newly Diagnosed Prostate Cancer Patient." US Too Prostate Support Group, Las Vegas, June 17, 2004. "The Indications and Side Effects of Hormone Blockade." Man-2-Man Prostate Support Group. Anaheim Memorial Hospital. July 7, 2004. "Tailoring Therapy for the Newly Diagnosed Patient." Prostate Cancer Support Group, Marina Del Rey. August 12, 2004. "Treatment Options for Relapsed Prostate Cancer." US-Too, Phoenix. October 23, 2004. "New Options for Prostate Cancer." Santa Monica, November 8, 2004. "Management of Relapsed Prostate Cancer." COPE-Support Group, Huntington Hospital. December 2, 2004. "Prostate Cancer Update." Physician CME Lecture. Daniel Freeman Marina Hospital, May 6, 2005. "Hormone Resistant Prostate Cancer." Wellness Community Westlake. May 21, 2005.

Memberships:
American Society of Hematology American Society of Clinical Oncology Cancer Committee, Daniel Freeman Memorial Hospital Advisory Board, Prostate Cancer Research Institute

Clinical Trials in Progress for Prostate Cancer:
Modified Citrus Pectin, the Effect on PSA Doubling time Preventions of Gynecomastia with an Aromitase Inhibitor Femara Comparative effect of Dutesteride on Dihydrotestosterone and Finesteride Phase II trial of Nilutamide. Androgen Replacement for Prostate Cancer Patients with Testicular Failure Effect of DN-101 and Taxotere in AIPC Patients who Have Previously Failed Taxotere The Impact of Dostinex on PSA Doubling Time The Prevention of Bone Loss with Oral Bisphosphonates The Effect of Finesteride on Prolonging Time Off in Patients on Intermittent Hormone Blockade Lack of Benefit of Local Therapy for Men with Preexisting AIPC Prognostic Significance of Negative Biopsy after 12 Months of Hormone Blockade.